Monteris Medical Announces Publication of Largest Cohort to Date of LITT for the Treatment of the Most Aggressive Brain Tumors

Study Demonstrates Benefits of LITT Using the NeuroBlate® System for Patients With Newly Diagnosed and Recurrent Wild-Type IDH Glioblastoma

MINNETONKA, Minn., June 1, 2022 /PRNewswire/ — Monteris Medical announced today that an article on interstitial laser thermotherapy (LITT) for patients diagnosed with HDI savageglioblastoma-like, the most common and aggressive brain tumor, was published in the journal, Advances in neuro-oncology. Data from 89 patients collected through the prospective multicenter LAANTERN registry showed that LITT offers an effective alternative to traditional surgery for patients with newly diagnosed and recurrent glioblastoma while providing the benefits of minimally invasive surgery, including including a short recovery time. and a reduced potential for side effects.

The publication demonstrated that for newly diagnosed patients treated with LITT followed by standard chemotherapy and radiotherapy, overall survival (16.14 months) and progression-free survival (11.93 months) are comparable to published results. when traditional surgery was used. For patients with recurrent disease, no standard of care is currently established; however, this study showed a post-LITT median survival of nearly nine months, compared to the 5-13 month range seen for traditional surgery. Moreover, the functional status of the patients stabilized or improved at one month post-LITT.

HDI (isocitrate dehydrogenase – a genetic mutation) wild-type glioblastomas require immediate intervention. With standard treatment, median overall survival for glioblastoma is estimated at 15-18 months with less than 10% of patients alive at five years. Other molecularly defined gliomas may be less common than HDI wild-type, but they are known to have longer survival rates. Therefore, it is becoming increasingly important to stratify research by subtype and molecular features to control for variability in survival rates across all types of gliomas.

dr. Jean de Grootsenior author of the article and head of the neuro-oncology division at University of California San Francisco Weill Institute for Neurosciences, said: “For patients with glioblastoma, treatment options are limited, especially for those with recurrent disease. These data clearly demonstrate that LITT remains an essential tool to achieve maximal and safe tumor cytoreduction and is particularly effective when followed by chemotherapy and radiotherapy. The minimally invasive nature of LITT, the short recovery period, and the favorable side effect profile make LITT a safe and effective option.”

Approximately 25,000 primary brain tumors are diagnosed in United States every year. Of these, approximately 15% are glioblastomas. Those glioblastomas which are molecularly defined as HDI wild-type tumors tend to grow quickly and have a worse prognosis than other tumor types.

Martin J. EmersonPresident and CEO of Monteris, said, “Congratulations to the physicians at LAANTERN and their research teams on the publication of this pivotal study in LITT and primary brain tumors. We are very grateful to the patients who gave their time and energy to participate in this study. The body of evidence that continues to emerge in support of laser ablation has firmly established LITT’s position in the continuum of care for patients with brain tumors and epilepsy.


LAANTERN is a post-marketing study designed to evaluate the performance and use of the NeuroBlate® System in the standard of care and “real world” setting. This is the first prospective multicenter laser ablation study. All sites operate under an IRB-approved protocol and are subject to rigorous data management and monitoring practices to ensure data quality and consistency. The registry will follow up to 3,000 patients for five years assessing safety, quality of life, health economics and procedural outcomes, including survival and freedom from seizures.

About Monteris and the NeuroBlate System

Monteris Medical is a private company that develops and markets innovative MRI-guided ablation systems to perform minimally invasive, robot-controlled brain surgery, commonly referred to as laser ablation, LITT (Laser Interstitial Thermal Therapy) or SLA (Stereotactic Laser Ablation). ). The Monteris NeuroBlate System is the only minimally invasive system that allows a robotic interface for the precise and safe delivery of laser energy. The Monteris Medical NeuroBlate System is a neurosurgical tool intended for the ablation of intracranial soft tissue, including brain structures such as brain tumors, radiation necrosis, and epileptic foci (as identified by noninvasive and invasive neurodiagnostic testing , including imaging). For more information, visit

Media Contact:
Monteris Medical Corp.
Jim Erickson
Financial director
[email protected]

SOURCE Monteris Medical

Jacob L. Thornton